Horizon Pharma Announces Settlement of DUEXIS(R) Patent Litigation With Par Pharmaceutical

DEERFIELD, IL--(Healthcare Sales & Marketing Network) - Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that it has entered into settlement and license agreements with Par Pharmaceutical Companies, Inc. and its subsidiary Par Pharmaceutical, Inc., to r... Biopharmaceuticals, Generics, Litigation, LicensingHorizon Pharma, Par Pharmaceutical, DUEXIS, ibuprofen, famotidine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news